Extended Low-Dose Apixaban Reduces Risk of Recurrent VTE: HI-PRO Trial Results
Sina Rashedi, Postdoctoral Research Fellow at Brigham and Women’s Hospital, Harvard Medical School, shared a post on X:
”Honored to be a part of the HI-PRO trial, presented today by my mentor Gregory Piazza at ESC Congress 2025
Published in NEJM.
In provoked VTE and enduring risk,
Extended low-dose apixaban vs placebo:
Decreased risk of recurrent VTE with low risk of major.”
Read the full article here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber
Stay updated on the latest scientific advancements with Hemostasis Today.
-
Jun 8, 2026, 12:21William Aird: Developing Patient-Facing Educational Material for The Blood Project
-
Jun 8, 2026, 12:02Glanzmann Thrombasthenia – A Rare but Important Platelet Disorder – Iranian Comprehensive Hemophilia Care Center
-
Jun 8, 2026, 06:30Caryn Blumenfeld: Team Zakophilia and Ratner’s Runners Even Though It’s A Walk!
-
Jun 8, 2026, 06:25Cécile Jefford: The NEHA Community and the Power of Human Connection
-
Jun 8, 2026, 06:02Manoj K: How Incyte Could Help Transform Care for Patients With von Willebrand Disease
-
Jun 8, 2026, 03:05Shamsunisha Yusuff: Iron Down, Platelets Up in a Young CBC ?
-
Jun 8, 2026, 03:03Samwel Mikaye: D-Dimer – A Marker of Blood Clot Breakdown
-
Jun 8, 2026, 02:59Vinita Madhuri: Our Engagement, A Lifeline for Thalassemia Patients
-
Jun 7, 2026, 22:11Lucia Härtel: Exercise, IL-10 Signaling, and Post-Stroke Brain Plasticity